CD8A and diffuse large B-cell lymphoma: Furthermore, immune checkpoint molecules such as PD-1 and TIM-3 mediate the exhaustion of CD8+ T cells, underscoring the necessity of investigating novel immune checkpoint inhibitors in DLBCL treatment strategies.